Comparison between Shanti Gold International IPO and Veeda Clinical Research IPO.
Shanti Gold International IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Veeda Clinical Research IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Shanti Gold International IPO is up to ₹360.11 Cr whereas the issue size of the Veeda Clinical Research IPO is up to ₹0.00 Cr. The final issue price of Shanti Gold International IPO is ₹199.00 per share and of Veeda Clinical Research IPO is .
| Shanti Gold International IPO | Veeda Clinical Research IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹2 per share |
| Issue Price (Lower) | ₹189.00 per share | |
| Issue Price (Upper) | ₹199.00 per share | |
| Issue Price (Final) | ₹199.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 75 shares | |
| Fresh Issue Size | 1,80,96,000 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹360.11 Cr | up to ₹185.00 Cr |
| OFS Issue Size | 0 shares | 1,30,08,128 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 1,80,96,000 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹360.11 Cr | up to ₹0.00 Cr |
Shanti Gold International IPO opens on Jul 25, 2025, while Veeda Clinical Research IPO opens on . The closing date of Shanti Gold International IPO and Veeda Clinical Research IPO is Jul 29, 2025, and , respectively.
| Shanti Gold International IPO | Veeda Clinical Research IPO | |
|---|---|---|
| Anchor Bid Date | Jul 24, 2025 | |
| Issue Open | Jul 25, 2025 | |
| Issue Close | Jul 29, 2025 | |
| Basis Of Allotment (Tentative) | Jul 30, 2025 | |
| Initiation of Refunds (Tentative) | Jul 31, 2025 | |
| Credit of Share (Tentative) | Jul 31, 2025 | |
| Listing date (Tentative) | Aug 01, 2025 | |
| Anchor Lockin End date 1 | Aug 29, 2025 | |
| Anchor Lockin End date 2 | Oct 28, 2025 |
Shanti Gold International IPO P/E ratio is 19.24, as compared to Veeda Clinical Research IPO P/E ratio of .
| Shanti Gold International IPO | Veeda Clinical Research IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Shanti Gold International Ltd.'s revenue increased by 56% and profit after tax (PAT) rose by 108% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 99.99 | 33.83 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 74.89 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 19.24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹1434.71 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 25.70% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.60 | 0.32 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹10.34 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 44.85% | -0.02% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Shanti Gold International IPO Retail Individual Investors (RII) are offered 63,33,600 shares while in Veeda Clinical Research IPO retail investors are offered 63,33,600 shares. Qualified Institutional Buyers (QIB) are offered 36,19,200 shares in Shanti Gold International IPO and in Veeda Clinical Research IPO.
| Shanti Gold International IPO | Veeda Clinical Research IPO | |
|---|---|---|
| Anchor Investor Reservation | 54,28,800 shares | |
| Market Maker Reservation | 0 shares | |
| QIB | 36,19,200 shares | |
| NII | 27,14,400 shares | |
| RII | 63,33,600 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 1,80,96,000 shares |
Shanti Gold International IPO subscribed 80.78x in total, whereas Veeda Clinical Research IPO subscribed .
| Shanti Gold International IPO | Veeda Clinical Research IPO | |
|---|---|---|
| QIB (times) | 117.33x | |
| NII (times) | 151.17x | |
| Big NII (times) | 173.08x | |
| Small NII (times) | 107.35x | |
| RII (times) | 29.73x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 80.78x |
